Pfenex has developed a high-quality protein production and bioanalytic technology platform approach that allows us to create biosimilars in a highly efficient manner.
We believe we are one of the only companies focused on non-glycosylated biosimilars, creating a differentiated platform approach and competitive advantage. This focus allows us to ensure a robust pipeline of high-quality therapeutics.
In addition, our unique protein production platform is well suited to vaccine development. By capitalizing on our ability to rapidly identify production strains for antigens that cannot be readily produced in other systems we enable infectious disease research and vaccine development that was previously not possible.
See our complete product pipeline below.